サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1534247

腎臓がん治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）

Global Kidney Cancer Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 222 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
腎臓がん治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 222 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腎臓がん治療薬の市場規模は、2023年の67億2,000万米ドルから、2032年には116億1,000万米ドル近くに達し、調査期間2024年～2032年のCAGRは6.26%と推定されます。

腎臓がん治療薬とは、腎細胞がん（RCC）としても知られる腎臓がんの治療に使用される医薬品を指します。これらの薬剤には、腎臓におけるがん細胞の増殖と転移を阻害するように設計された標的療法、免疫療法、化学療法剤が含まれます。標的療法は通常、がん細胞の増殖や血管新生に関与する特定の分子をブロックし、免疫療法はがん細胞を認識・破壊する免疫系の能力を高めます。また、分裂の早いがん細胞を死滅させるために、特定の症例では化学療法薬が使用されることもあります。治療法の選択は、がんの病期、腫瘍に存在する遺伝子変異、患者の全身状態などの要因によって決まります。

市場力学

世界的に腎臓がんの罹患率が上昇していることに加え、意識の高まりと早期発見への取り組みが、効果的な腎臓がん治療薬への需要を牽引しています。腎臓がんは世界で最も多いがんのトップ10に入っており、患者の予後を改善するために治療アプローチの継続的な革新が必要とされています。分子生物学と遺伝子プロファイリングの進歩により、腎臓がんに関連する分子変化に特異的に対処する標的療法が開発されています。チロシンキナーゼ阻害剤（TKI）や哺乳類ラパマイシン標的（mTOR）阻害剤を含む標的療法は、進行腎細胞がんと診断された患者において、がん細胞の増殖を抑制し、無増悪生存期間を延長する有効性を実証しています。さらに、免疫療法は腎臓がんの治療法を一変させ、特にチェックポイント阻害剤は免疫系を解き放ちがん細胞を攻撃します。プログラム細胞死タンパク質1（PD-1）と細胞傷害性Tリンパ球関連タンパク質4（CTLA-4）を標的とする治療薬は、臨床試験で有望な結果を示しており、従来の治療に反応しない患者に新たな治療選択肢を提供しています。さらに、製薬会社と研究機関の協力体制は、腎臓がん治療薬の開発におけるイノベーションの原動力となっています。パートナーシップは、新規バイオマーカーの同定、併用療法の探索、治療選択肢の拡大と患者の転帰改善のための臨床試験の実施に重点を置いています。しかし、革新的な腎臓がん治療薬へのアクセスは、規制上のハードル、償還政策、価格の問題によって制限される可能性があり、これが市場の成長を抑制する可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは腎臓がん治療薬の世界市場における各セグメントを包括的に評価することもできます。腎臓がん治療薬産業の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

腎臓がん治療薬市場レポートのこのセクションでは、国別および地域別のセグメントに関する詳細なデータを提供することで、戦略担当者がそれぞれの製品またはサービスのターゲット層を特定し、今後のビジネスチャンスに役立てることができます。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカの地域展望をカバーし、腎臓がん治療薬市場の現在と将来の需要を明らかにしています。さらに、すべての主要地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 腎臓がん治療薬- 産業分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 腎臓がん治療薬の世界市場分析：がんタイプ別

  • 概要：がんタイプ別
  • 実績データと予測データ分析：がんタイプ別
  • 腎細胞がん（RCC）
  • 移行細胞がん
  • ウィルムス腫瘍
  • 腎肉腫

第6章 腎臓がん治療薬の世界市場分析：治療法別

  • 概要：治療法別
  • 実績データと予測データ分析：治療法別
  • 標的療法
  • 免疫療法
  • 化学療法
  • その他の治療法

第7章 腎臓がん治療薬の世界市場分析：薬剤クラス別

  • 概要：薬剤クラス別
  • 実績データと予測データ分析：薬剤クラス別
  • 血管新生阻害薬
  • モノクローナル抗体
  • Mtor阻害剤
  • サイトカイン免疫療法（IL-2）
  • その他の薬剤クラス別

第8章 腎臓がん治療薬の世界市場分析：投与経路別

  • 概要：投与経路別
  • 実績データと予測データ分析：投与経路別
  • 経口
  • 静脈内
  • 皮下投与

第9章 腎臓がん治療薬の世界市場分析：流通チャネル別

  • 概要：流通チャネル別
  • 実績データと予測データ分析：流通チャネル別
  • 院内薬局
  • 実店舗
  • eコマース

第10章 腎臓がん治療薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要・実績・予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要・実績・予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋の売上分析
    • 概要・実績・予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカの売上分析
    • 概要・実績・予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要・実績・予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第11章 腎臓がん治療薬企業の競合情勢

  • 腎臓がん治療薬市場の競合
  • パートナーシップ/提携/協定
  • 合併・買収
  • 新製品の上市
  • その他の開発

第12章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Active Biotech AB
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co. Ltd.
  • Exelixis Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GSK Plc
  • Helsinn Healthcare SA
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Cancer Type (USD MN)
  • Renal Cell Carcinoma (RCC) Market Sales By Geography (USD MN)
  • Transitional Cell Cancer Market Sales By Geography (USD MN)
  • Wilms Tumor Market Sales By Geography (USD MN)
  • Renal Sarcoma Market Sales By Geography (USD MN)
  • Analysis By Therapy (USD MN)
  • Targeted Therapy Market Sales By Geography (USD MN)
  • Immunotherapy Market Sales By Geography (USD MN)
  • Chemotherapy Market Sales By Geography (USD MN)
  • Other Therapies Market Sales By Geography (USD MN)
  • Analysis By Drug Class (USD MN)
  • Angiogenesis Inhibitors Market Sales By Geography (USD MN)
  • Monoclonal Antibodies Market Sales By Geography (USD MN)
  • Mtor Inhibitors Market Sales By Geography (USD MN)
  • Cytokine Immunotherapy (IL-2) Market Sales By Geography (USD MN)
  • Other Drug Classes Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Brick and Mortar Market Sales By Geography (USD MN)
  • E-Commerce Market Sales By Geography (USD MN)
  • Global Kidney Cancer Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Kidney Cancer Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Kidney Cancer Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Cancer Type
  • Market Attractiveness Analysis By Therapy
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Cancer Type (USD MN)
  • Renal Cell Carcinoma (RCC) Market Sales By Geography (USD MN)
  • Transitional Cell Cancer Market Sales By Geography (USD MN)
  • Wilms Tumor Market Sales By Geography (USD MN)
  • Renal Sarcoma Market Sales By Geography (USD MN)
  • Global Market Analysis By Therapy (USD MN)
  • Targeted Therapy Market Sales By Geography (USD MN)
  • Immunotherapy Market Sales By Geography (USD MN)
  • Chemotherapy Market Sales By Geography (USD MN)
  • Other Therapies Market Sales By Geography (USD MN)
  • Global Market Analysis By Drug Class (USD MN)
  • Angiogenesis Inhibitors Market Sales By Geography (USD MN)
  • Monoclonal Antibodies Market Sales By Geography (USD MN)
  • Mtor Inhibitors Market Sales By Geography (USD MN)
  • Cytokine Immunotherapy (IL-2) Market Sales By Geography (USD MN)
  • Other Drug Classes Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Brick and Mortar Market Sales By Geography (USD MN)
  • E-Commerce Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112115310

The global demand for Kidney Cancer Drugs Market is presumed to reach the market size of nearly USD 11.61 Billion by 2032 from USD 6.72 Billion in 2023 with a CAGR of 6.26% under the study period 2024-2032.

Kidney cancer drugs refer to pharmaceutical agents used in the treatment of kidney cancer, also known as renal cell carcinoma (RCC). These drugs include targeted therapies, immunotherapies, and chemotherapy agents designed to inhibit the growth and spread of cancer cells in the kidneys. Targeted therapies typically block specific molecules involved in cancer cell proliferation and angiogenesis, while immunotherapies enhance the immune system's ability to recognize & destroy cancer cells. Chemotherapy drugs may also be used in certain cases to kill rapidly dividing cancer cells. The choice of treatment depends on factors such as cancer stage, genetic mutations present in the tumor, and the patient's overall health.

MARKET DYNAMICS

The rising incidence of kidney cancer globally, coupled with increasing awareness and early detection efforts, is driving demand for effective kidney cancer drugs. Kidney cancer is among the top ten most common cancers worldwide, necessitating continued innovation in treatment approaches to improve patient outcomes. Advancements in molecular biology and genetic profiling have led to the development of targeted therapies that specifically address molecular alterations associated with kidney cancer. Targeted therapies, including tyrosine kinase inhibitors (TKIs) & mammalian target of rapamycin (mTOR) inhibitors, have demonstrated efficacy in inhibiting cancer cell growth and prolonging progression-free survival in individuals diagnosed with advanced renal cell carcinoma. Moreover, immunotherapy has revolutionized the treatment landscape for kidney cancer, particularly checkpoint inhibitors that unleash the immune system to attack cancer cells. Drugs targeting programmed cell death protein 1 (PD-1) & cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown promising results in clinical trials, offering new therapeutic alternatives for patients who do not respond to conventional treatments. Furthermore, collaborative efforts between pharmaceutical companies & research institutions drive innovation in developing kidney cancer drugs. Partnerships focus on identifying novel biomarkers, exploring combination therapies, and conducting clinical trials to expand treatment options and improve patient outcomes. However, access to innovative kidney cancer drugs can be limited by regulatory hurdles, reimbursement policies, and affordability issues, which may restrain market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Kidney Cancer Drugs. The growth and trends of Kidney Cancer Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Kidney Cancer Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Cancer Type

  • Renal Cell Carcinoma (RCC)
  • Transitional Cell Cancer
  • Wilms Tumor
  • Renal Sarcoma

By Therapy

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Other Therapies

By Drug Class

  • Angiogenesis Inhibitors
  • Monoclonal Antibodies
  • Mtor Inhibitors
  • Cytokine Immunotherapy (IL-2)
  • Other Drug Classes

By Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

By Distribution Channel

  • Hospital Pharmacy
  • Brick and Mortar
  • E-Commerce

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Kidney Cancer Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Kidney Cancer Drugs market include Active Biotech AB, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eisai Co. Ltd., Exelixis Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GSK Plc, Helsinn Healthcare SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. KIDNEY CANCER DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Cancer Type
    • 3.7.2 Market Attractiveness Analysis By Therapy
    • 3.7.3 Market Attractiveness Analysis By Drug Class
    • 3.7.4 Market Attractiveness Analysis By Route of Administration
    • 3.7.5 Market Attractiveness Analysis By Distribution Channel
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY CANCER TYPE

  • 5.1. Overview By Cancer Type
  • 5.2. Historical and Forecast Data Analysis By Cancer Type
  • 5.3. Renal Cell Carcinoma (RCC) Historic and Forecast Sales By Regions
  • 5.4. Transitional Cell Cancer Historic and Forecast Sales By Regions
  • 5.5. Wilms Tumor Historic and Forecast Sales By Regions
  • 5.6. Renal Sarcoma Historic and Forecast Sales By Regions

6. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY THERAPY

  • 6.1. Overview By Therapy
  • 6.2. Historical and Forecast Data Analysis By Therapy
  • 6.3. Targeted Therapy Historic and Forecast Sales By Regions
  • 6.4. Immunotherapy Historic and Forecast Sales By Regions
  • 6.5. Chemotherapy Historic and Forecast Sales By Regions
  • 6.6. Other Therapies Historic and Forecast Sales By Regions

7. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY DRUG CLASS

  • 7.1. Overview By Drug Class
  • 7.2. Historical and Forecast Data Analysis By Drug Class
  • 7.3. Angiogenesis Inhibitors Historic and Forecast Sales By Regions
  • 7.4. Monoclonal Antibodies Historic and Forecast Sales By Regions
  • 7.5. Mtor Inhibitors Historic and Forecast Sales By Regions
  • 7.6. Cytokine Immunotherapy (IL-2) Historic and Forecast Sales By Regions
  • 7.7. Other Drug Classes Historic and Forecast Sales By Regions

8. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 8.1. Overview By Route of Administration
  • 8.2. Historical and Forecast Data Analysis By Route of Administration
  • 8.3. Oral Historic and Forecast Sales By Regions
  • 8.4. Intravenous Historic and Forecast Sales By Regions
  • 8.5. Subcutaneous Historic and Forecast Sales By Regions

9. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 9.1. Overview By Distribution Channel
  • 9.2. Historical and Forecast Data Analysis By Distribution Channel
  • 9.3. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 9.4. Brick and Mortar Historic and Forecast Sales By Regions
  • 9.5. E-Commerce Historic and Forecast Sales By Regions

10. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE KIDNEY CANCER DRUGS COMPANIES

  • 11.1. Kidney Cancer Drugs Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF KIDNEY CANCER DRUGS INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Active Biotech AB
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Amgen Inc.
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Astellas Pharma Inc.
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. AstraZeneca PLC
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. Bayer AG
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. Bristol-Myers Squibb Company
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Eisai Co. Ltd.
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. Exelixis Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments
  • 12.11. F. Hoffmann-La Roche Ltd.
    • 12.11.1 Company Overview
    • 12.11.2 Company Revenue
    • 12.11.3 Products
    • 12.11.4 Recent Developments
  • 12.12. Genentech Inc.
    • 12.12.1 Company Overview
    • 12.12.2 Company Revenue
    • 12.12.3 Products
    • 12.12.4 Recent Developments
  • 12.13. GSK Plc
    • 12.13.1 Company Overview
    • 12.13.2 Company Revenue
    • 12.13.3 Products
    • 12.13.4 Recent Developments
  • 12.14. Helsinn Healthcare SA
    • 12.14.1 Company Overview
    • 12.14.2 Company Revenue
    • 12.14.3 Products
    • 12.14.4 Recent Developments
  • 12.15. Johnson & Johnson Services Inc.
    • 12.15.1 Company Overview
    • 12.15.2 Company Revenue
    • 12.15.3 Products
    • 12.15.4 Recent Developments
  • 12.16. Merck & Co. Inc.
    • 12.16.1 Company Overview
    • 12.16.2 Company Revenue
    • 12.16.3 Products
    • 12.16.4 Recent Developments
  • 12.17. Novartis AG
    • 12.17.1 Company Overview
    • 12.17.2 Company Revenue
    • 12.17.3 Products
    • 12.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies